Literatur

• Literatur

• 1 Schuele SU, Lueders HO. Intractable epilepsy: management and therapeutic alternatives. Lancet Neurol 2008; 07: 514-24.
• 2 Ben-Menachem E. et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007; 48: 1308-17.
• 3 Ben-Menachem E. Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs of Today 2008; 44: 35-40.
• 4 Beyreuther BK. et al. Lacosamide: a review of preclinical properties. CNS Drug Reviews 2007; 13: 21-42.
• 5 Doty P. et al. Lacosamide. Neurotherapeutics 2007; 04: 145-48.
• 6 Stöhr T, Wasterlain C. Lacosamide in in vitro and in vivo animal models for neuroprotection. PosterPräsentation bei der 60. Jahrestagung der American Epilepsy Society, San Diego, Dezember. 2006
• 7 Vimpat® Fachinformation; Stand. August 2008
• 8 Horstmann R. et al. SPM does not interact with valproic acid and carbamazepine. Poster-Präsentation bei der 57. Jahrestagung der American Epilepsy Society, Boston. Dezember 2003
• 9 Nickel B. et al. Population pharmacocinetics of lacosamide in subjects with partial-onset seizures: Results from two phase III trials. Poster-Präsentation bei der 62. Jahrestagung der American Epilepsy Society, Seattle. Dezember 2008
• 10 Halasz P. et al. Adjunctive lacosamide for partialonset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009; 50: 443-53.
• 11 Chung S. et al. Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial. Epilepsia Jan. 2010 Epub ahead of print.
• 12 Rosenfeld W. et al. Lacosamide: An interim Evaluation of long-term safety and efficacy as oral adjunctive therapy in subjects with partial-onset seizures. Poster-Präsentation der 61. Jahrestagung der American Epilepsy Society, Philadelphia. Dezember 2007
• 13 Rosenfeld W. et al. Long-term safety and tolerability of lacosamide for partial-onset seizures: an interim evaluation of patients exposed to lacosamide in double-blind and open-label trials. Poster-Präsentation der 63. Jahrestagung der American Epilepsy Society, Boston. Dezember 2009
• 14 Ben-Menachem E. et al. Long-term efficacy of lacosamide for partial-onset seizures: An interim evaluation of completer cohorts exposed to lacosamide for up to 36 months. Poster-Präsentation der 63. Jahrestagung der American Epilepsy Society, Boston. Dezember 2009
• 15 Gil-Nagel A. et al. The safety and tolerability of lacosamide in randomized, double-blind, placebo-controlled phase II/III clinical trials. Poster-Präsentation beim 28. Internationalen Epilepsiekongress, Budapest. Juli 2009
• 16 Biton V. et al. Intravenous lacosamide as replacement for oral lacosamide in patients with partialonset seizures. Epilepsia 2008; 49: 418-24.
• 17 Krauss G. et al. Intravenous lacosamide as shortterm replacement for oral lacosamide in partialonset seizures. Epilepsia. 2010 im Druck.
• 18 Wehner T. et al. Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009; 16: 423-25.
• 19 Arnold S, Beige A. Lacosamide for the treatment of focal epilepsies: post-marketing experience in 40 patients. Poster-Präsentation der 63. Jahrestagung der American Epilepsy Society, Boston. Dezember 2009
• 20 Meencke H-J, Dehnicke C, Bartels S. Clinical experience with lacosamide in difficult to treat, drug resistant patients. Poster-Präsentation der 63. Jahrestagung der American Epilepsy Society, Boston. Dezember 2009
• 21 Schneider F. et al. Effectiveness and tolerability of lacosamide in adult patients with refractory partial epilepsy. Poster-Präsentation der 63. Jahrestagung der American Epilepsy Society, Boston. Dezember 2009
• 22 Mayer T, Lutz M. An open-label trial of lacosamide as add-on therapy for refractory partial-onset seizures. Poster-Präsentation der 63. Jahrestagung der American Epilepsy Society, Boston. Dezember 2009
• 23 Kellinghaus C. et al. Intravenous lacosamide for treatment of status epilepticus. Poster-Präsentation der 63. Jahrestagung der American Epilepsy Society, Boston. Dezember 2009
• 24 Almeida L, Soares-da-Silva P. Eslicarbazepine Acetate (BIA 2-093). Neurotherapeutics 2007; 04: 88-96.
• 25 Volosov A. et al. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther 1999; 66: 547-53.
• 26 Bonifácio MJ. et al. Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia 2001; 42: 600-8.
• 27 Benes J. et al. Anticonvulsant and sodium channelblocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J Med Chem 1999; 42: 2582-7.
• 28 Learmonth DA. et al. Synthesis, anticonvulsant properties and pharmacokinetic profile of novel 10,11-dihydro-10-oxo-5H-dibenz/b,f/azepine- 5-carboxamide derivatives. Eur J Med Chem 2001; 36: 227-36.
• 29 Bialer M. et al. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 2004; 61: 1-48.
• 30 Almeida L. et al. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol 2008; 64: 267-73.
• 31 European Medicines Agency. CHMP assessment report for Zebinix. 2009 http://www.emea.europa.eu/humandocs/PDFs/EPAR/zebinix/H-988-en6 pdf; Stand 23.11.2009.
• 32 Almeida L, Soares-da-Silva P. Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. J Clin Pharmacol 2004; 44: 906-18.
• 33 Maia J. et al. Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). Drugs R D 2005; 06: 201-6.
• 34 Almeida L. et al. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2—093) in healthy elderly and young subjects. J Clin Pharmacol 2005; 45: 1062-6.
• 35 Falcão A. et al. Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. Biopharm Drug Dispos 2007; 28: 249-56.
• 36 Bialer M. et al. Investigation of the influence of eslicarbazepine acetate on the plasma concentrations of concomitant antiepileptic drugs in partial epilepsy. Epilepsia. 2009 50. (suppl.4): 156.
• 37 Fachinformation Zebinix, Stand. April 2009
• 38 Fuseau E. et al. Population pharmacokinetics of eslicarbazepine acetate in adult patients with refractory partial seizures. Epilepsia 2008; 49 (Suppl. 07) 432.
• 39 Elger C. et al. BIA-2093-301 Investigators Study Group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, doubleblind, placebo-controlled, parallel-group phase III study. Epilepsia 2009; 50: 454-63.
• 40 Gil-Nagel A. et al. BIA-2093-303 Investigators Study Group. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 2009; 120: 281-7.
• 41 Halasz P. et al. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): Results of a one-year open-label extension to study BIA-2093-301. Epilepsia 2008; 49 (Suppl. 07) 435-6.
• 42 Gabbai AA. et al. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): Results of a one-year open-label extension to study BIA-2093-302. Epilepsia 2008; 49 (Suppl. 07) 432-3.
• 43 Lopes-Lima J. et al. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): Results of a one-year open-label extension to study BIA-2093-303. Epilepsia 2008; 49 (Suppl. 07) 441-2.
• 44 Levy RH. et al. (eds). Drugs in development – Rufinamide. In Antiepileptic drugs. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2002: 906-912.
• 45 McLean MJ. et al. The influence of rufinamide on sodium currents and action potential firing in rodent neurons (abstract). Epilepsia 2005; 46 (Suppl. 08) 269.
• 46 White HS. et al. The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia 2008; 49: 1213-20.
• 47 Bialer M. et al. Progress report on new antiepileptic drugs: A summary of the third Eilat conference. Epilepsy Res 1996; 25: 299-319.
• 48 Cheung WK. et al. Intraand intersubject variabilities of CGP 33101 after replicate single oral doses of two 200-mg tablets and 400-mg suspension. Pharm Res 1995; 12: 1878-82.
• 49 16 Eisai Ltd, Fachinformation Inovelon®, Stand. April 2008
• 50 Bialer M. et al. Progress report on new antiepileptic drugs: A summary of the fourth Eilat conference. Epilepsy Res 1999; 34: 1-41.
• 51 Svendsen KD. et al. Single center, open-label, multiple-dose pharmacokinetic trial investigating the effect of rufinamide administration on OrthoNovum 1/35 in healthy women [abstract]. Epilepsia 1998; 39 (Suppl. 06) 59.
• 52 Perucca E. et al. Rufinamide: Clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008; 49: 1123-41.
• 53 Bialer M. et al. Progress report on new antiepileptic drugs: A summary of the fifth Eilat conference. Epilepsy Res 2001; 43: 11-58.
• 54 Arroyo S. Rufinamide. Neurother 2007; 04: 155-162.
• 55 Glauser T. et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008; 49: 1950-8.
• 56 Glauser T. et al. Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome [abstract]. Epilepsia 2005; 46 (Suppl. 06) 408.
• 57 Kluger G. et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: First European experience. Epilepsy Behav 2009; 14: 491-5.
• 58 Krauss G, Perdomo C, Arroyo S. Short-term and long-term safety of rufinamide in patients with epilepsy [abstract]. Epilepsia 2005; 46 (Suppl. 08) 213.
• 59 Hancock E, Cross H. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2003; 03: CD003277.
• 60 Korff C. et al. Dravet syndrom (Severe Myoklonic Epilepsy in Infancy): A retrospective study of 16 Patients. Journal of Child Neurology 2007; 22: 185-194.
• 61 Desitin Arzneimittel GmbH, Hamburg. Diacomit® (Stiripentol). Produkt-Monographie. 2007
• 62 Trojnar MK. et al. Stiripentol. A novel antiepileptic drug. Pharmacological Reports 2005; 57: 154-160.
• 63 Quilichini P. et al. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABAA-receptor channels. Epilepsia 2006; 47: 704-16.
• 64 Chiron C. et al. Stiripentol in severe myoclonic epilepsy in infancy: A randomized placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000; 356: 1638-1642.
• 65 Chiron C. Stiripentol. Expert Opin Investig Drugs 2005; 14: 905-911.
• 66 Chiron C. Stiripentol. Neurotherapeutics 2007; 04: 123-125.
• 67 Rascol O. et al. A pilot study of stiripentol, a new anticonvulsant drug, in complex partial seizures uncontrolled by carbamazepine. Clinical Neuropharmacology 1989; 12: 119-123.
• 68 Desitin Arzneimittel GmbH, Hamburg, Fachinformation Diacomit®; Stand Dezember. 2007
• 69 Perez J. et al. Stiripentol: Efficacy and tolerability in children with Epilepsy. Epilepsia 1999; 40: 1618-1626.
• 70 Chiron C. et al. Stiripentol in childhood partial epilepsy: randomizid placebo-controlled trial with enrichment and withdrawal design. Journal of Child Neurology 2006; 21: 496-502.
• 71 EPAR. European Public assessment Report. EMEA. 2007